Asston Pharmaceuticals IPO
Asston Pharmaceuticals IPO Details
-
Open Date
09 Jul 2025
-
Close Date
11 Jul 2025
-
Listing Date
16 Jul 2025
- IPO Price Range
₹ 115 to ₹123
- IPO Size
₹ 26.17 Cr
- Listing Exchange
BSE SME
Asston Pharmaceuticals IPO Timeline
Asston Pharmaceuticals IPO Subscription Status
| Date | QIB | NII | Individual Investors | Total |
|---|---|---|---|---|
| 09-Jul-25 | 3.51 | 0.66 | 1.22 | 1.75 |
| 10-Jul-25 | 4.47 | 19.67 | 16.66 | 13.84 |
| 11-Jul-25 | 85.76 | 353.14 | 172.06 | 186.55 |
Last Updated: 29 September 2025 3:28 PM by 5paisa
Asston Pharmaceuticals Limited is launching its ₹26.17 crore IPO. The company exports a wide range of pharmaceutical products—tablets, capsules, syrups, and more—across key therapeutic areas like antibiotics, vitamins, and analgesics. It operates through direct sales and contract manufacturing on a principle-to-principle basis. With certifications from Central and State FDA and NQA accreditation, Asston adheres to strict Quality Management System (QMS) standards, ensuring consistent product quality.
Established in: 2019
Managing Director: Dr. Ashish Narayan Sakalkar
Peers
Shelter Pharma Limited
Bafna Pharmaceuticals Limited
Trident Lifeline Limited
Asston Pharmaceuticals Objectives
To fund machinery purchases for capital expenditure in the manufacturing unit.
To meet the company's increased working capital requirements.
To repay or prepay the company’s existing borrowings.
General corporate purposes.
Asston Pharmaceuticals IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹26.17 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹26.17 Cr |
Asston Pharmaceuticals IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹2,30,000 |
| Retail (Max) | 2 | 2,000 | ₹2,30,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,45,000 |
| S-HNI (Max) | 8 | 8,000 | ₹9,20,000 |
| B-HNI (Min) | 9 | 9,000 | ₹10,35,000 |
Asston Pharmaceuticals IPO Reservation
| Investors Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB | 85.76 | 4,25,000 | 3,64,49,000 | 448.32 |
| NII (HNI) | 353.14 | 3,22,000 | 11,37,10,000 | 1,398.63 |
| Individual Investors (IND category bidding for 2 Lots) | 172.06 | 7,46,000 | 12,83,58,000 | 1,578.80 |
| Total** | 186.55 | 14,93,000 | 27,85,17,000 | 3,425.76 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (in Rs. Crores) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 7.19 | 15.84 | 25.61 |
| EBITDA | 1.52 | 2.55 | 6.16 |
| PAT | 1.06 | 1.36 | 4.33 |
| Particulars (in Rs. Crores) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Total Assets | 13.69 | 20.26 | 28.12 |
| Share Capital | 0.70 | 0.78 | 6.27 |
| Total Borrowings | 5.25 | 6.82 | 7.26 |
| Particulars (in Rs. Crores) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net Cash Generated From / (used in) operating activities | -0.32 | -3.80 | -0.16 |
| Net Cash Generated From / (used in) investing activities | -0.91 | -0.01 | 0.87 |
| Net Cash Generated From / (used in) financing activities | 1.21 | 3.69 | 0.51 |
| Net Increase (Decrease) In Cash And Cash Equivalents | 0.01 | 0.12 | 0.19 |
Strengths
1. Experienced leadership and skilled workforce ensure consistent operations and strong strategic decision-making capabilities.
2. In-house quality assurance systems help maintain strict compliance and superior product quality standards.
3. Asset-light model reduces fixed costs through reliance on trusted contract manufacturers and distributors.
4. Strategic location near ports enables faster logistics, supporting efficient domestic and international operations.
Weaknesses
1. Heavy dependence on third-party manufacturers limits control over production schedules and quality assurance.
2. Business relies mainly on export markets, exposing it to geopolitical and currency exchange risks.
3. Limited logistics partnerships may hamper flexibility in global supply chain and shipping operations.
4. Over-reliance on one freight forwarder poses risks to distribution continuity and timely deliveries.
Opportunities
1. Expand export of affordable generics to underserved markets with growing healthcare infrastructure needs.
2. Explore inorganic growth through acquisitions and strategic alliances in key global regions.
3. Leverage digital platforms and CRM tools to boost sales and customer engagement globally.
4. Increase contract manufacturer network to scale operations and diversify production capabilities efficiently.
Threats
1. Changing global regulations may increase compliance costs, impacting margins and operational flexibility.
2. Stiff competition in the generics segment can pressure pricing, market share, and profitability levels.
3. Quality control lapses could lead to product recalls, legal issues, and reputational damage.
4. Disruptions from pandemics or geopolitical events may severely affect export-driven revenue streams.
1. Asston’s revenue has grown from ₹7.19 crore to ₹25.61 crore in just two years.
2. FY25 margins are strong with EBITDA at 24.6% and PAT margin touching 17.3% levels.
3. Return ratios are impressive with RoE and RoCE both above 50%, showing efficient capital use.
4. Anchor investors subscribed ₹7.81 crore, adding credibility to this fairly valued SME IPO at ₹115–123.
1. Indian pharma exports reached $28.5 billion in first half 2025, growing ~13.4% year-over-year.
2. Domestic market projected to grow from ~$58 billion to $120–130 billion by 2030.
3. Indian CDMO market expanding at ~10.6% CAGR, from $8.1 billion in 2023 to ~$20 billion by 2032.
4. India holds 752 US FDA‑approved plants, strengthening global quality compliance and export capacity.
- Companies
- Type
- Opening On
-
Physicswallah
- Mainboard
- 11th Nov
- Pre-Book
-
Emmvee Photovoltaic Power
- Mainboard
- 11th Nov
- Pre-Book
-
Tenneco Clean Air India
- Mainboard
- 12th Nov
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Asston Pharmaceuticals IPO opens from July 9, 2025 to July 11, 2025.
The size of Asston Pharmaceuticals IPO is ₹27.56 Cr.
The price band of Asston Pharmaceuticals IPO is fixed at ₹115 to ₹123 per share.
To apply for Asston Pharmaceuticals IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Asston Pharmaceuticals IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Asston Pharmaceuticals IPO is 2,000 shares and the investment required is ₹₹230,000.
The share allotment date of Asston Pharmaceuticals IPO is July 14, 2025
The Asston Pharmaceuticals IPO will likely be listed on July 16, 2025.
Sobhagya Capital Options Ltd. is the book running lead manager for Asston Pharmaceuticals IPO.
Asston Pharmaceuticals plans to utilise the raised capital from the IPO for:
- To fund machinery purchases for capital expenditure in the manufacturing unit.
- To meet the company's increased working capital requirements.
- To repay or prepay the company’s existing borrowings.
- General corporate purposes.
Asston Pharmaceuticals Contact Details
Asston Pharmaceuticals Limited
4th Floor, Office No. A-431 Balaji Bhavan,
Plot No 42A Sector-11 CBD Belapur,
Navi Mumbai, Thane
Navi Mumbai, Maharashtra, 400614
Phone: +91 22 49731411
Email: info@asstonpharmaceuticals.com
Website: https://www.asstonpharmaceuticals.com/
Asston Pharmaceuticals IPO Register
Maashitla Securities Private Limited
Phone: +91-11-45121795-96
Email: ipo@maashitla.com
Website: https://maashitla.com/allotment-status/public-issues
Asston Pharmaceuticals IPO Lead Manager
Sobhagya Capital Options Ltd